Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications
- PMID: 28618420
- DOI: 10.1159/000473881
Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications
Abstract
Gastric cancer (GC) represents a global health concern. Despite advances in prevention, diagnosis, and therapy, GC is still the third leading cause of cancer mortality worldwide, with more than 720,000 estimated deaths in 2012. Overall survival for advanced disease is about 1 year, a dismal prognosis that is partly due to the high levels of biological heterogeneity found in GC. Indeed, GC is a highly heterogeneous disease from morphological and molecular standpoints. The numerous histological and molecular classifications currently available reflect such heterogeneity. Although recent high-throughput studies cluster the molecular data obtained into subgroups with clinical relevance, we still need a practical, prognostic, and predictive classification system, integrating morphological and molecular features, towards the identification of novel therapeutic targets. It is noteworthy that GC heterogeneity encompasses not only interpatient variability (intertumour heterogeneity), but also variations within the same tumour (intratumour heterogeneity). The latter encompasses spatial heterogeneity (in different tumour areas) and temporal heterogeneity (along progression from primary to recurrent and/or metastatic disease). In this review, we analyse the morphological, immunophenotypic, and molecular heterogeneity in GC as the basis for a better understanding of the disease, and discuss the practical implications for diagnostic pathology, prognostic evaluation, and precision therapy.
Keywords: Gastric cancer; Intratumour heterogeneity; Molecular heterogeneity; Morphological heterogeneity; Stomach.
© 2017 S. Karger AG, Basel.
Similar articles
-
Comparison and applicability of molecular classifications for gastric cancer.Cancer Treat Rev. 2019 Jul;77:29-34. doi: 10.1016/j.ctrv.2019.05.005. Epub 2019 May 28. Cancer Treat Rev. 2019. PMID: 31195213 Review.
-
Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives.World J Gastroenterol. 2019 Oct 14;25(38):5773-5788. doi: 10.3748/wjg.v25.i38.5773. World J Gastroenterol. 2019. PMID: 31636471 Free PMC article. Review.
-
Dissection of gastric cancer heterogeneity for precision oncology.Cancer Sci. 2019 Nov;110(11):3405-3414. doi: 10.1111/cas.14191. Epub 2019 Sep 25. Cancer Sci. 2019. PMID: 31495054 Free PMC article. Review.
-
Recent advances in the molecular diagnostics of gastric cancer.World J Gastroenterol. 2015 Sep 14;21(34):9838-52. doi: 10.3748/wjg.v21.i34.9838. World J Gastroenterol. 2015. PMID: 26379391 Free PMC article. Review.
-
Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma.Pathol Int. 2024 Jun;74(6):301-316. doi: 10.1111/pin.13427. Epub 2024 Apr 23. Pathol Int. 2024. PMID: 38651937 Free PMC article. Review.
Cited by
-
A Molecular Stratification of Chilean Gastric Cancer Patients with Potential Clinical Applicability.Cancers (Basel). 2020 Jul 10;12(7):1863. doi: 10.3390/cancers12071863. Cancers (Basel). 2020. PMID: 32664343 Free PMC article.
-
Emodin is a Potential Drug Targeting CD44-positive Hepatocellular Cancer.Curr Cancer Drug Targets. 2024;24(5):510-518. doi: 10.2174/0115680096256913231101103719. Curr Cancer Drug Targets. 2024. PMID: 38099524
-
Evaluation of Immune Infiltration Based on Image Plus Helps Predict the Prognosis of Stage III Gastric Cancer Patients with Significantly Different Outcomes in Northeastern China.Dis Markers. 2022 Mar 25;2022:2893336. doi: 10.1155/2022/2893336. eCollection 2022. Dis Markers. 2022. PMID: 35371344 Free PMC article.
-
Clinicopathological differences, risk factors and prognostic scores for western patients with intestinal and diffuse-type gastric cancer.World J Gastrointest Oncol. 2022 Jun 15;14(6):1162-1174. doi: 10.4251/wjgo.v14.i6.1162. World J Gastrointest Oncol. 2022. PMID: 35949214 Free PMC article.
-
Comprehensive Analysis of Alternative Splicing in Gastric Cancer Identifies Epithelial-Mesenchymal Transition Subtypes Associated with Survival.Cancer Res. 2022 Feb 15;82(4):543-555. doi: 10.1158/0008-5472.CAN-21-2117. Cancer Res. 2022. PMID: 34903603 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous